将患者中心获益作为晚期卵巢癌维持治疗随机试验的终点:GCIG症状获益委员会立场文件
GCIG症状获益委员会召开头脑风暴会议,通过文献回顾、试验分析和国际专家意见,针对晚期卵巢癌维持治疗试验中患者报告结局(PROM)的整合提出四项指导原则,以支持无进展生存期(PFS)主要终点,并统一未来GCIG试验中PROM的收集、分析和报告。
要点
- 推荐在维持治疗试验设计早期遵循SPIRIT-PRO指南。
- 需统一PROM的选择、收集与报告,并联合健康相关生活质量(HRQL)与临床终点。
- 应建立处理不完整HRQL数据的共同方法,以支持跨试验比较。
核心结论
- 密切整合HRQL和PROM对解读卵巢癌维持治疗临床试验结果至关重要。
- 所有GCIG试验应采用一致方法评估和报告患者中心获益,以支持跨试验比较并指导实践。
研究设计与样本
- GCIG症状获益委员会召开头脑风暴会议,通过文献回顾、试验分析和国际专家意见识别四个相关主题。
主要发现
- GCIG SBC一致接受在未来维持治疗试验中整合PROM的重要性,并制定四项指导原则供试验设计早期考虑。
关键数值与推荐
- 四项指导原则:1)遵循SPIRIT-PRO指南;2)统一PROM的选择、收集和报告;3)联合HRQL措施与临床终点;4)处理不完整HRQL数据的共同方法。
临床怎么用
- 在卵巢癌维持治疗试验设计早期即应遵循SPIRIT-PRO指南并统一PROM的收集与报告。
- 将HRQL措施与PFS等临床终点结合分析,并采用共同方法处理不完整HRQL数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Quality of life and patient reported outcome measures (PROMs) are important secondary endpoints and incorporated in most contemporary clinical trials. There have been deficiencies in their assessment and reporting in ovarian cancer clinical trials, particularly in trials of maintenance treatment where they are of particular importance. The Gynecologic Cancer InterGroup (GCIG) symptom benefit committee (SBC) recently convened a brainstorming meeting with representation from all collaborative groups to address questions of how to best incorporate PROMs into trials of maintenance therapies to support the primary endpoint which is usually progression free survival (PFS). These recommendations should harmonize the collection, analysis and reporting of PROM's across future GCIG trials. METHODS: Through literature review, trials analysis and input from international experts, the SBC identified four relevant topics to address with respect to promoting the role of PROMs to support the PFS endpoint in clinical trials of maintenance treatment for OC. RESULTS: The GCIG SBC unanimously accepted the importance of integrating PROM's in future maintenance trials and developed four guiding principles to be considered early in trial design. These include 1) adherence to SPIRIT-PRO guidelines, 2) harmonization of selection, collection and reporting of PROM's; 3) combining Health Related Quality of Life (HRQL) measures with clinical endpoints and 4) common approaches to dealing with incomplete HRQL data. CONCLUSIONS: Close attention to incorporating HRQL and PROM's is critical to interpret the results of ovarian cancer clinical trials of maintenance therapies. There should be a consistent approach to assessing and reporting patient centered benefits across all GCIG trials to enable cross trial comparisons which can be used to inform practice.
引用
- Kurtz JE, Gebski V, Sukhin V, et al. Incorporating patient centered benefits as endpoints in randomized trials of maintenance therapies in advanced ovarian cancer: A position paper from the GCIG symptom benefit committee. Gynecol Oncol. 2021. PMID: 33612336. doi:10.1016/j.ygyno.2021.02.018
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。